Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Early Feasibility Study of the Capstan Medical TMVR System

A legfontosabb adatok

Ki végzi
Capstan Medical
Hol
Cincinnati, Nashville és San Francisco (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
15 fő, tervezett
Kezdés
2026. nov.
Várható befejezés
2032. márc.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Capstan Compass Robotic System for Transcatheter Mitral Valve Replacement
A regiszteradat frissítve
2026. november 9.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 37 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years at the time of consent
  • Moderate-to-severe or severe mitral regurgitation
  • NYHA II or greater symptoms
  • The participant is considered to be at elevated, but not prohibitive, surgical risk for mitral valve replacement, as determined by the local multi-disciplinary heart team and/or a validated surgical risk assessment tool (e.g., STS PROM)
  • The local multi-disciplinary heart team determines that surgical mitral valve replacement is not the preferred treatment option and that the participant is an appropriate candidate for treatment with the Capstan System
  • The local multi-disciplinary heart team determines that the participant is unsuitable for mitral transcatheter edge-to-edge repair (mTEER) due to anatomical, technical, and/or clinical reasons
  • The local multi-disciplinary heart team deems heart failure management is optimized based on participant characteristics and applicable guidelines
  • Ability and willingness to provide written informed consent prior to any study related procedure(s)

Ki nem vehet részt

  • Prior mitral valve intervention that would interfere with the appropriate placement of the Capstan Valve
  • Any cardiac or vascular procedure performed within 30 days prior to procedure
  • Myocardial infarction within 30 days prior to enrollment
  • Concurrent medical condition with a life expectancy of less than 12 months
  • Participant is on the waiting list for a heart transplant or has had a prior heart transplant
  • Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.))
  • Untreated severe aortic or pulmonic valve disease (stenosis or regurgitation)
  • Untreatable severe right ventricular dysfunction or severe tricuspid valve disease
  • Cardiac resynchronization therapy (CRT) device implanted within 30 days of procedure
  • Active endocarditis, other ongoing infection requiring antibiotic therapy
  • Stroke or transient ischemic attack (TIA) within 30 days of procedure
  • Active peptic ulcer or active gastrointestinal bleeding
  • Known allergy or hypersensitivity to device materials (e.g. nitinol, PET), or a documented allergy to heparin, that cannot be adequately medicated; a history of HIT, or contraindication to required antithrombotic therapies
  • Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits
  • Clinically significant untreated coronary artery disease requiring revascularization
  • Chronic Obstructive Pulmonary Disease (COPD) on continuous O2 therapy
  • Planned cardiac intervention in the next 12 months
  • LVEF < 25%
  • End-stage renal failure on dialysis or eGFR ≤ 25
  • Pregnant (participants of childbearing age are required to have a negative pregnancy test)
  • Anatomic features unsuitable for the Capstan System
  • Inappropriate anatomy for femoral venous introduction and delivery of the Capstan System
  • Severe mitral stenosis
  • Evidence of intracardiac thrombus, vegetation, or mass
  • PASP > 70mmHg or PVR > 5 Wood units after vasodilator challenge
  • Contraindication to or inability to tolerate the protocol-required therapeutic anticoagulation regimen for the 6-months post-procedure period
  • Participant is contraindicated for transesophageal echocardiography (TEE)
  • Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
  • Refusal of blood products

Helyszínek itt: Egyesült Államok

  • The Christ HospitalCincinnati, Egyesült ÁllamokContact: Susie FrakesRésztvevőt keres
  • Vanderbilt University Medical CenterNashville, Egyesült ÁllamokContact: Kathryn AdamsToborzás még nem indult
  • Kaiser PermanenteSan Francisco, Egyesült ÁllamokContact: Cristina Casias-PerezToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This early feasibility study is evaluating the safety and performance of the Capstan Compass Robotic System™ for transcatheter mitral valve replacement in patients with symptomatic, moderate-to-severe or severe mitral regurgitation who are unsuitable for surgical repair or transcatheter edge-to-edge repair.

A vizsgálat csoportja

  • TMVRA vizsgált kezelés

    Participants will undergo transcatheter mitral valve replacement

    Kezelés: Capstan Compass Robotic System for Transcatheter Mitral Valve Replacement

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. november 9.